Ignite Creation Date:
2024-05-05 @ 11:23 AM
Last Modification Date:
2024-10-26 @ 9:06 AM
Study NCT ID:
NCT00015704
Status:
COMPLETED
Last Update Posted:
2021-11-01
First Post:
2001-05-01
Brief Title:
Effect of Interleukin-2 on HIV Treatment Interruption
Sponsor:
National Institute of Allergy and Infectious Diseases NIAID
Organization:
National Institute of Allergy and Infectious Diseases NIAID
Study Overview
Official Title:
An Open-Label Pilot Study Utilizing CD4 T-Cell Counts Lower Than 350 Cellsmm3 as the Threshold for Restarting Therapy With Potent Antiretroviral Therapy With or Without Interleukin-2 to Determine the Effect of Pulse Therapy on the Characteristics of Treatment Interruptions
Status:
COMPLETED
Status Verified Date:
2021-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Interleukin-2 IL-2 helps the body make infection-fighting white blood cells including CD4 and CD8 T cells One HIV treatment strategy is planned treatment interruption stopping anti-HIV drugs when CD4 count and level of virus in the blood are at certain levels The purpose of this study is to see if IL-2 used with potent anti-HIV drugs allows for longer HIV treatment interruptions
Detailed Description:
One approach in reconstituting an HIV-diminished immune system is the use of potent antiretroviral therapy ART in conjunction with IL-2 IL-2 is a cytokine secreted by activated T cells that regulates the proliferation and differentiation of CD4 and CD8 T cells Although treatment with IL-2 can cause temporary increases in HIV viral load clinical studies with IL-2 have revealed no long-term adverse effects on viral load IL-2 therapy may also help purge the hosts latent viral reservoir through activation of resting lymphocytes harboring provirus Another approach to managing HIV infection is strategic treatment interruption Results from small pilot trials suggest that HIV replication can be highly suppressed over consecutive courses of ART following short treatment interruptions and CD4 T cell counts can be maintained on these interruptions with some positive effect on HIV-specific immunity This study will evaluate potent ART started and interrupted based on CD4 cell counts with or without IL-2
Patients will be stratified based on lifetime CD4 T-cell nadir lowest measurement into one of three groups Group 1 will have a nadir of 200 CD4 cellsmm3 Group 2 will have a nadir greater than 200 CD4 cellsmm3 and patients with no documented nadir count available will join Group 3 Within each group patients will be randomly assigned to one of two study arms Arm A patients will receive pulses of potent ART with IL-2 while Arm B patients will receive pulses of potent ART alone Patients in Arm A will receive potent ART with IL-2 given by subcutaneous injection twice daily for 5 days every 8 weeks for at least 17 weeks Arm B patients will receive potent ART alone for at least 17 weeks Both groups then go on treatment interruption for approximately 64 weeks followed by potent ART alone for an additional 24 weeks Patients will repeat this cycle of potent ART with or without IL-2 treatment interruption and potent ART alone throughout the study This study will last approximately 4 years
Clinical and laboratory assessments will be performed periodically throughout the study CD4 T cell counts and viral load will determine if a patient can enter the next treatment step Potent ART is not provided by this study
A5109s is a limited-center substudy designed to determine whether viral replication impairs lymphocyte proliferation in vivo Patients at substudy-participating sites will register to the substudy immediately after beginning their first treatment interruption in the main study
Patients will be stratified based on lifetime CD4 T-cell nadir lowest measurement into one of three groups Group 1 will have a nadir of 200 CD4 cellsmm3 Group 2 will have a nadir greater than 200 CD4 cellsmm3 and patients with no documented nadir count available will join Group 3 Within each group patients will be randomly assigned to one of two study arms Arm A patients will receive pulses of potent ART with IL-2 while Arm B patients will receive pulses of potent ART alone Patients in Arm A will receive potent ART with IL-2 given by subcutaneous injection twice daily for 5 days every 8 weeks for at least 17 weeks Arm B patients will receive potent ART alone for at least 17 weeks Both groups then go on treatment interruption for approximately 64 weeks followed by potent ART alone for an additional 24 weeks Patients will repeat this cycle of potent ART with or without IL-2 treatment interruption and potent ART alone throughout the study This study will last approximately 4 years
Clinical and laboratory assessments will be performed periodically throughout the study CD4 T cell counts and viral load will determine if a patient can enter the next treatment step Potent ART is not provided by this study
A5109s is a limited-center substudy designed to determine whether viral replication impairs lymphocyte proliferation in vivo Patients at substudy-participating sites will register to the substudy immediately after beginning their first treatment interruption in the main study
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 10179 | REGISTRY | DAIDS ES Registry Number | None |